Clinical Trial: NRG GY026

NRG GY026

Status: Open

NCT#05256225

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

GY026 accrual of Stage I-II Patients is reopened to accrual, effective March 18, 2025 with the implementation of Amendment 8.

The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Available Clinical Trials

Clinical Trial: NRG GY026

NRG GY026

NCT#05256225

Navigation

About Us

Contact Us